Patent expirations push biopharma industry toward a tougher 2026
In this week’s episode of “The Top Line,” we take a deep dive into the fourth-quarter performance of the biopharma industry and how the sector fared in 2025 overall. As the world’s 25 largest biopharm...
13 Mar 17min
As AI evolves, the modern R&D lab is changing
The design of the modern R&D lab may be due for a rethink. Artificial intelligence and automation are reshaping how science gets done, yet many of the physical spaces where research happens were built...
6 Mar 20min
How physiology powers biotech innovation (Sponsored)
Physiology connects genes and molecules to whole-body function, shaping every stage of drug discovery and development. In this sponsored episode of The Top Line, Sue Bodine, president-elect of the Ame...
2 Mar 13min
Autoimmune CAR-T: Navigating the FDA’s new regulatory playbook
For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases. But the application of these engineered cell therapies is expanding to re...
27 Feb 23min
Inside the sterile fill capacity crunch (Sponsored)
What does the future hold for sterile fill-finish CDMOs in a rapidly evolving market? In this sponsored episode of The Top Line, Denis Johnson, CEO of Grand River Aseptic Manufacturing, discusses the ...
23 Feb 9min
Trump's tariff threats, measured by manufacturing
Though uncertainty still surrounds the Trump administration’s pharmaceutical import tariffs, the trade rhetoric set off a clear response across the industry in 2025. Drugmakers accelerated U.S. manufa...
20 Feb 14min
Why patient access must keep pace with drug innovation (Sponsored)
Biopharmaceutical innovation is advancing at an unprecedented pace, yet many patients still face barriers to accessing new medicines. In this episode of Health Matters, John O’Brien, president and CEO...
16 Feb 27min
What were the biggest clinical trial flops of 2025?
Every clinical setback carries lessons. That’s why Fierce revisits major trial failures each year: not to dwell on disappointment, but to understand what went wrong and what it signals for the road ah...
13 Feb 19min
